— Know what they know.
Not Investment Advice

VERA NASDAQ

Vera Therapeutics, Inc.
1W: -13.2% 1M: -14.7% 3M: -17.7% YTD: -29.4% 1Y: +61.7% 3Y: +346.1% 5Y: +198.7%
$34.04
-0.31 (-0.90%)
 
Weekly Expected Move ±6.9%
$32 $35 $37 $40 $42
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 29 · $2.4B mcap · 58M float · 2.04% daily turnover · Short 50% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NO EDGE
33.5 / 100
NoneWeakNarrowWide
Primary source: Network Effects  ·  ROIC: 924.5%
Cost Advantage
33
Intangibles
25
Switching Cost
38
Network Effect
47
Scale
27
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. VERA has No discernible competitive edge (33.5/100). The business operates without significant structural advantages. The primary source of advantage is Network Effects. ROIC of 924.5% confirms the company is generating returns well above its cost of capital — a hallmark of durable competitive advantages.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$91
Low
$91
Avg Target
$91
High
Based on 1 analyst since May 7, 2026 earnings
Analyst Recommendations
Strong Buy: 1Buy: 12Hold: 1Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$91.00
Analysts1
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-05-15 Evercore ISI $97 $91 -6 +136.1% $38.54
2025-12-19 Goldman Sachs Initiated $95 +99.2% $47.69
2025-12-11 Wedbush Laura Chico $34 $33 -1 -27.3% $45.42
2025-12-08 Evercore ISI Gavin Clark-Gartner Initiated $97 +111.9% $45.78
2025-12-05 Pivotal Research Initiated $73 +71.3% $42.61
2025-11-28 H.C. Wainwright $15 $90 +75 +170.0% $33.33
2025-06-03 Scotiabank Greg Harrison Initiated $65 +110.3% $30.91
2024-03-21 Wedbush Laura Chico Initiated $34 -20.7% $42.87
2024-01-26 Raymond James Ryan Deschner $29 $37 +8 +22.6% $30.18
2023-12-18 Raymond James Ryan Deschner Initiated $29 +83.1% $15.84
2023-01-04 Jefferies Initiated $6 -5.8% $6.37
2023-01-04 H.C. Wainwright $35 $15 -20 -18.0% $18.30
2022-11-18 J.P. Morgan Initiated $38 +115.7% $17.62
2022-05-02 H.C. Wainwright Initiated $35 +75.0% $20.00

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C
May 22, 2026
DCF
3
ROE
1
ROA
1
D/E
3
P/E
1
P/B
1
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. VERA receives an overall rating of C. Areas of concern: ROE (1/5), ROA (1/5), P/E (1/5), P/B (1/5).
Rating Change History
DateFromTo
2026-05-20 C- C
2026-05-08 C C-
2026-05-04 C- C
2026-04-30 C C-
2026-03-02 C- C
2026-02-26 C C-

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

Grade A+
Profitability
Balance Sheet
20
Earnings Quality
48
Growth
Value
35
Momentum
Safety
100
Cash Flow

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
11.27
Safe Zone
Piotroski F-Score
2/9
Beneish M-Score
Ohlson O-Score
-4.09
Bankruptcy prob: 1.6%
Low Risk
Credit Rating
BBB+
Score: 64.4/100
Trend: Deteriorating
Earnings Quality
OCF/NI: 0.79x
Accruals: -10.9%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. VERA scores 11.27, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. VERA scores 2/9, suggesting weak financial fundamentals — the company fails the majority of these accounting tests. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. VERA's implied 1.6% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. VERA receives an estimated rating of BBB+ (score: 64.4/100), with a deteriorating trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-6.58x
PEG
0.13x
P/S
0.00x
P/B
4.86x
P/FCF
-9.79x
P/OCF
EV/EBITDA
-6.18x
EV/Revenue
EV/EBIT
-6.16x
EV/FCF
-7.62x
Earnings Yield
-12.83%
FCF Yield
-10.22%
Shareholder Yield
0.00%
Graham Number
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. VERA currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
1.000
NI / EBT
×
Interest Burden
1.015
EBT / EBIT
×
EBIT Margin
EBIT / Rev
×
Asset Turnover
0.000
Rev / Assets
×
Equity Multiplier
1.177
Assets / Equity
=
ROE
-62.4%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. VERA's ROE of -62.4% is driven by A tax burden ratio of 1.00 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
Price/Value
Margin of Safety
Premium
Assessment
Overvalued

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1262 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$34.04
Median 1Y
$26.83
5th Pctile
$5.76
95th Pctile
$127.34
Ann. Volatility
95.4%
Analyst Target
$91.00
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Marshall Fordyce, M.D.
President and Chief Executive Officer
$660,000 $2,356,285 $6,986,410
David Johnson Operating
rating Officer
$510,000 $784,942 $2,721,412
Robert Brenner, M.D.
Chief Medical Officer
$509,000 $784,942 $2,719,852
Sean Grant Financial
ancial Officer
$507,000 $784,942 $2,716,732
William Turner Regulatory
latory Officer
$473,000 $656,550 $2,346,180

CEO Pay Ratio

5229:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $6,986,410
Avg Employee Cost (SGA/emp): $1,336
Employees: 75,000

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
75,000
+66864.3% YoY
Revenue / Employee
Profit / Employee
$-3,995
NI: $-299,615,000
SGA / Employee
$1,336
Avg labor cost proxy
R&D / Employee
$2,870
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
ROE 3.8% 12.4% -40.1% -64.6% 5.7% 7.4% -1.2% -1.4% -1.5% -1.4% -1.1% -1.1% -1.2% -1.5% -44.8% -51.7% -64.3% -74.2% -50.7% -62.4% -62.45%
ROA -6.3% -20.3% -33.3% -53.7% -81.6% -1.1% -82.8% -94.8% -99.8% -95.5% -62.5% -61.4% -70.3% -87.5% -36.6% -42.2% -52.5% -60.6% -43.1% -53.1% -53.07%
ROIC 3.2% 7.2% 4.5% 7.2% 8.6% 11.3% 11.1% 12.9% 13.7% 13.3% 15.1% 15.1% 17.4% 21.6% 14.6% 16.9% 20.6% 23.6% 7.6% 9.2% 9.25%
ROCE -6.6% -21.2% -36.6% -59.0% -73.8% -96.0% -84.9% -96.4% -1.0% -95.6% -61.4% -59.7% -67.8% -84.5% -22.9% -26.6% -33.4% -38.8% -42.3% -53.4% -53.37%
Gross Margin
Operating Margin
Net Margin
EBITDA Margin
FCF Margin
OCF Margin
ROE 3Y Avg snapshot only -61.39%
ROE 5Y Avg snapshot only -76.30%
ROA 3Y Avg snapshot only -43.57%
ROIC Economic snapshot only -44.42%
Cash ROA snapshot only -39.91%
Valuation
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
P/E Ratio -40.51 -33.40 -20.38 -12.65 -6.53 -7.89 -6.04 -2.86 -6.62 -5.92 -7.12 -23.31 -18.36 -18.06 -15.26 -8.72 -6.89 -7.36 -10.86 -7.79 -6.580
P/S Ratio 0.000
P/B Ratio -1.56 -4.13 8.17 8.18 5.30 8.33 6.99 3.80 9.24 7.91 6.72 21.61 19.47 23.86 4.02 2.65 2.60 3.21 5.38 4.76 4.858
P/FCF -18.16 -28.06 -29.02 -19.91 -9.22 -10.96 -7.95 -3.44 -8.49 -6.90 -7.41 -22.03 -18.53 -16.63 -14.46 -8.44 -7.11 -8.77 -13.46 -9.79 -9.787
P/OCF
EV/EBITDA -25.27 -28.82 -17.80 -11.06 -5.24 -6.92 -5.06 -2.04 -5.89 -5.19 -6.09 -22.61 -18.00 -17.90 -12.06 -5.67 -4.36 -5.22 -9.11 -6.18 -6.177
EV/Revenue
EV/EBIT -24.90 -28.54 -17.71 -11.02 -5.23 -6.92 -5.06 -2.05 -5.89 -5.19 -6.13 -22.87 -18.02 -17.91 -12.01 -5.62 -4.35 -5.19 -9.07 -6.16 -6.156
EV/FCF -11.16 -23.98 -25.21 -17.29 -7.35 -9.54 -6.72 -2.46 -7.49 -5.95 -6.25 -20.95 -17.52 -15.90 -10.81 -5.20 -4.34 -6.00 -10.82 -7.62 -7.618
Earnings Yield -2.5% -3.0% -4.9% -7.9% -15.3% -12.7% -16.6% -34.9% -15.1% -16.9% -14.0% -4.3% -5.4% -5.5% -6.6% -11.5% -14.5% -13.6% -9.2% -12.8% -12.83%
FCF Yield -5.5% -3.6% -3.4% -5.0% -10.8% -9.1% -12.6% -29.1% -11.8% -14.5% -13.5% -4.5% -5.4% -6.0% -6.9% -11.9% -14.1% -11.4% -7.4% -10.2% -10.22%
PEG Ratio snapshot only 0.135
Price/Tangible Book snapshot only 4.757
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Current Ratio 22.55 22.55 10.73 10.73 10.73 10.73 4.91 4.91 4.91 4.91 7.71 7.71 7.71 7.71 25.67 25.67 25.67 25.67 13.64 13.64 13.635
Quick Ratio 22.55 22.55 10.73 10.73 10.73 10.73 4.91 4.91 4.91 4.91 7.71 7.71 7.71 7.71 25.67 25.67 25.67 25.67 13.64 13.64 13.635
Debt/Equity -0.00 -0.00 0.07 0.07 0.07 0.07 0.41 0.41 0.41 0.41 0.53 0.53 0.53 0.53 0.09 0.09 0.09 0.09 0.13 0.13 0.128
Net Debt/Equity -1.07 -1.07 -1.07 -1.07 -1.08 -1.08 -1.08 -1.08 -1.05 -1.05 -1.05 -1.05 -1.02 -1.02 -1.02 -1.02 -1.05 -1.05 -1.054
Debt/Assets 0.00 0.00 0.06 0.06 0.06 0.06 0.24 0.24 0.24 0.24 0.31 0.31 0.31 0.31 0.08 0.08 0.08 0.08 0.11 0.11 0.105
Debt/EBITDA -0.00 -0.00 -0.18 -0.11 -0.09 -0.07 -0.35 -0.31 -0.29 -0.31 -0.57 -0.58 -0.52 -0.41 -0.38 -0.33 -0.26 -0.22 -0.27 -0.21 -0.213
Net Debt/EBITDA 15.84 4.90 2.70 1.67 1.33 1.02 0.93 0.81 0.78 0.82 1.13 1.16 1.03 0.83 4.07 3.53 2.79 2.41 2.22 1.76 1.759
Interest Coverage -1393.70 -324.93 -211.01 -176.88 -90.53 -58.37 -42.05 -30.39 -24.86 -18.97 -17.87 -19.02 -18.95 -22.36 -28.21 -32.61 -25.63 -32.22 -32.225
Equity Multiplier -0.61 -0.61 1.20 1.20 1.20 1.20 1.71 1.71 1.71 1.71 1.73 1.73 1.73 1.73 1.14 1.14 1.14 1.14 1.22 1.22 1.215
Cash Ratio snapshot only 13.368
Debt Service Coverage snapshot only -32.113
Cash to Debt snapshot only 9.244
FCF to Debt snapshot only -3.801
Defensive Interval snapshot only 683.4 days
Efficiency & Turnover
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Asset Turnover 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Inventory Turnover
Receivables Turnover 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Payables Turnover 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.08 -0.08 -0.08 -0.10 -0.14 -0.14 -0.14 -0.10 0.00 0.06 0.12 0.00 0.02 0.017
DSO
DIO 0 0 0 0.0 days
DPO 6089 3042 21075 21075.2 days
Cash Conversion Cycle
Fixed Asset Turnover snapshot only 0.000
Cash Velocity snapshot only 0.000
Growth (YoY)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue
Net Income -15.4% -5.6% -2.2% -1.3% -90.3% -39.9% -7.8% 7.6% -0.5% -30.8% -58.5% -86.1% -1.0% -87.5% -96.9% -1.1% -1.10%
EPS -5.4% -4.2% -1.4% -45.9% -16.4% 14.2% 32.6% 31.7% 18.7% -5.7% -28.3% -48.9% -73.6% -61.2% -68.3% -87.3% -87.32%
FCF -4.2% -3.0% -2.5% -2.0% -1.1% -66.6% -36.3% -17.5% -27.7% -65.4% -74.0% -81.7% -97.8% -44.9% -50.6% -62.1% -62.07%
EBITDA -15.5% -5.7% -2.2% -1.3% -90.1% -38.5% -5.6% 9.8% 2.3% -28.1% -51.9% -79.8% -1.0% -87.7% -99.5% -1.2% -1.18%
Op. Income -8.6% -4.6% -2.1% -1.3% -1.0% -46.9% -12.2% 3.1% -4.6% -33.8% -63.9% -89.7% -1.0% -86.0% -88.7% -98.4% -98.40%
OCF Growth snapshot only -88.85%
Asset Growth snapshot only 12.06%
Equity Growth snapshot only 4.74%
Debt Growth snapshot only 41.49%
Shares Change snapshot only 12.26%
Growth (CAGR)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 3Y
Revenue 5Y
EPS 3Y
EPS 5Y
Net Income 3Y
Net Income 5Y
EBITDA 3Y
EBITDA 5Y
Gross Profit 3Y
Gross Profit 5Y
Op. Income 3Y
Op. Income 5Y
FCF 3Y
FCF 5Y
OCF 3Y
OCF 5Y
Assets 3Y 47.6% 47.6% 98.6% 98.6% 98.6% 98.6% 77.5% 77.5% 77.48%
Assets 5Y
Equity 3Y 1.0% 1.0% 1.0% 1.0% 98.8% 98.8% 98.83%
Book Value 3Y 47.6% 46.7% 52.1% 52.3% 50.4% 60.6% 60.60%
Dividend 3Y
Growth Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue Stability 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Earnings Stability 1.00 0.96 0.83 0.63 0.89 0.96 0.93 0.85 0.91 0.93 0.87 0.80 0.803
Margin Stability
Rev. Growth Consistency 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Earn. Growth Consistency 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
FCF Positive Streak 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Earnings Persistence 0.50 0.84 0.97 0.97 1.00 0.88 0.50 0.50 0.50 0.50 0.50 0.50 0.500
Earnings Smoothness
ROE Trend -0.16 0.06 0.04 -0.13 0.79 0.82 0.85 0.89 0.11 0.01 0.005
Gross Margin Trend
FCF Margin Trend
Sustainable Growth Rate
Internal Growth Rate
Cash Flow Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
OCF/Net Income 2.23 1.19 0.70 0.64 0.71 0.72 0.76 0.83 0.78 0.86 0.96 1.06 0.99 0.90 0.89 0.88 0.85 0.83 0.80 0.79 0.795
FCF/OCF 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.21 1.19 1.17 1.14 1.01 1.00 1.00 1.002
FCF/Net Income snapshot only 0.796
CapEx/Revenue
CapEx/Depreciation snapshot only 0.406
Accruals Ratio 0.08 0.04 -0.10 -0.20 -0.24 -0.30 -0.20 -0.16 -0.22 -0.14 -0.02 0.04 -0.01 -0.09 -0.04 -0.05 -0.08 -0.10 -0.08 -0.11 -0.109
Sloan Accruals snapshot only 0.069
Cash Flow Adequacy snapshot only -475.971
Dividends & Buybacks
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio
FCF Payout Ratio
Total Payout Ratio
Div. Increase Streak
Chowder Number
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Net Buyback Yield -36.8% -13.9% -9.0% -24.1% -23.4% -14.9% -16.0% -39.3% -16.2% -18.9% -16.8% -13.1% -14.5% -11.9% -27.2% -22.6% -23.0% -18.6% -8.8% -10.1% -10.11%
Total Shareholder Return -36.8% -13.9% -9.0% -24.1% -23.4% -14.9% -16.0% -39.3% -16.2% -18.9% -16.8% -13.1% -14.5% -11.9% -27.2% -22.6% -23.0% -18.6% -8.8% -10.1% -10.11%
DuPont Factors
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Tax Burden (NI/EBT) 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Interest Burden (EBT/EBIT) 1.00 1.00 1.00 1.00 1.00 1.01 0.99 1.00 1.01 1.02 1.02 1.03 1.04 1.04 1.05 1.04 1.04 1.03 1.04 1.01 1.015
EBIT Margin
Asset Turnover 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Equity Multiplier -0.61 -0.61 1.20 1.20 -7.00 -7.00 1.47 1.47 1.47 1.47 1.72 1.72 1.72 1.72 1.22 1.22 1.22 1.22 1.18 1.18 1.177
Per Share
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
EPS (Diluted TTM) $-0.33 $-0.52 $-1.31 $-1.86 $-2.08 $-2.70 $-3.20 $-2.71 $-2.42 $-2.32 $-2.16 $-1.85 $-1.97 $-2.45 $-2.77 $-2.76 $-3.42 $-3.95 $-4.66 $-5.16 $-5.16
Book Value/Share $-8.51 $-4.20 $3.27 $2.87 $2.57 $2.56 $2.77 $2.04 $1.74 $1.73 $2.29 $1.99 $1.86 $1.85 $10.51 $9.06 $9.05 $9.04 $9.41 $8.46 $6.99
Tangible Book/Share $-8.51 $-4.20 $3.27 $2.87 $2.57 $2.56 $2.77 $2.04 $1.74 $1.73 $2.29 $1.99 $1.86 $1.85 $10.51 $9.06 $9.05 $9.04 $9.41 $8.46 $8.46
Revenue/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
FCF/Share $-0.73 $-0.62 $-0.92 $-1.18 $-1.48 $-1.94 $-2.43 $-2.26 $-1.89 $-1.99 $-2.08 $-1.96 $-1.95 $-2.66 $-2.92 $-2.85 $-3.31 $-3.31 $-3.76 $-4.11 $-4.11
OCF/Share $-0.73 $-0.62 $-0.92 $-1.18 $-1.47 $-1.94 $-2.43 $-2.25 $-1.89 $-1.99 $-2.07 $-1.96 $-1.95 $-2.20 $-2.45 $-2.44 $-2.90 $-3.29 $-3.75 $-4.10 $-4.10
Cash/Share $5.11 $2.52 $3.74 $3.29 $2.94 $2.93 $4.12 $3.04 $2.59 $2.58 $3.62 $3.15 $2.94 $2.93 $11.67 $10.06 $10.05 $10.04 $11.12 $10.00 $8.35
EBITDA/Share $-0.32 $-0.51 $-1.30 $-1.84 $-2.07 $-2.68 $-3.23 $-2.72 $-2.41 $-2.28 $-2.13 $-1.81 $-1.90 $-2.36 $-2.62 $-2.61 $-3.29 $-3.81 $-4.47 $-5.07 $-5.07
Debt/Share $0.00 $0.00 $0.23 $0.20 $0.18 $0.18 $1.13 $0.83 $0.71 $0.71 $1.21 $1.05 $0.98 $0.98 $1.00 $0.86 $0.86 $0.86 $1.20 $1.08 $1.08
Net Debt/Share $-5.11 $-2.52 $-3.51 $-3.09 $-2.76 $-2.75 $-3.00 $-2.21 $-1.88 $-1.88 $-2.41 $-2.10 $-1.96 $-1.95 $-10.68 $-9.21 $-9.19 $-9.18 $-9.92 $-8.92 $-8.92
Academic Models
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Altman Z-Score 11.270
Altman Z-Prime snapshot only 22.516
Piotroski F-Score 1 1 2 2 2 2 2 2 2 2 4 3 4 3 4 4 4 4 2 2 2
Beneish M-Score
Ohlson O-Score snapshot only -4.088
ROIC (Greenblatt) snapshot only -53.68%
Net-Net WC snapshot only $8.38
Credit
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Credit Rating snapshot only BBB+
Credit Score 20.00 20.00 61.06 61.83 63.30 63.72 48.84 31.54 60.94 53.89 47.88 62.31 62.58 62.25 65.58 65.67 65.68 65.63 64.90 64.36 64.362
Credit Grade snapshot only 8
Credit Trend snapshot only -1.305
Implied Spread (bps) snapshot only 225.000
Industry Credit Rank snapshot only 61
Sector Credit Rank snapshot only 57

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms